Stockhub

Brickell Biotech, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 August 2022

12 August 2022

26 July 2022

  • curprev 21:4621:46, 26 July 2022‎ Chris talk contribs‎ 878 bytes +878‎ Created page with "Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10,..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Brickell_Biotech,_Inc.’